Welcome to our dedicated page for Pliant Therapeutics news (Ticker: $PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pliant Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pliant Therapeutics's position in the market.
Pliant Therapeutics, Inc. (PLRX) announces two poster presentations at the EASL International Liver Congress in Milan, Italy. The presentations focus on the updated safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial and the TGF-beta inhibition in human liver explant tissue with biliary fibrosis. The company continues to lead in the discovery of novel therapeutics for fibrotic diseases.
Pliant Therapeutics, a leader in fibrotic disease therapeutics, reported positive safety and efficacy data from Phase 2a trials. They accelerated the BEACON-IPF Phase 2b trial and received regulatory clearance for the PLN-101325 muscular dystrophy program. Financially, they reported a net loss of $47.0 million, with $483.9 million in cash and investments as of March 31, 2024.
Pliant Therapeutics, a clinical-stage biotechnology company focusing on fibrotic diseases, will participate in investor events in May 2024. The events include discussions with key company executives, offering insights into the company's progress and future plans.
